Nevertheless, the diversity in NRF2 activation among the four tested LTTs highlights the complexity of cisplatin resistance even within one tumour entity and predicts that responses to NRF2 inhibition may likewise be highly variable in patients. Here, NFE2L2 is linked to neoplasm.